Committee Rejects FDA Proposal To Narrow Bioequivalence Margins
This article was originally published in The Pink Sheet Daily
Executive Summary
The Pharmaceutical Science and Clinical Pharmacology Advisory Committee doesn't see the additional criteria as necessary, but FDA could still impose narrower bioequivalence margins over its objections.